Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit

Summary by marketbeat.com
Olema Pharmaceuticals (NASDAQ:OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, CEO Sean Bohen said during a company discussion hosted by Brad Canino. Bohen described the disease area as a la

2 Articles

marketbeat.commarketbeat.com
Reposted by
watchlistnews.comwatchlistnews.com
Center

Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit

Olema Pharmaceuticals (NASDAQ:OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, CEO Sean Bohen said during a company discussion hosted by Brad Canino. Bohen described the disease area as a la

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Saturday, February 14, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

CFO icon

CFO

Breast Cancer icon

Breast Cancer

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal